CD8A and neoplasm: However, a large fraction of the tumor-resident CD8+ T-cells have phenotypic changes, with high levels of programmed death-1 (PD-1) and Tim-3, and low levels of the immune co-receptors CD27 and CD28, losing their anti-tumor functions [51].